San Diego, USA-based ACADIA Pharmaceuticals has announced the filing of a preliminary prospectus supplement to its effective shelf registration statement previously filed with the Securities and Exchange Commission relating to a proposed underwritten public offering of $75.0 million of its common stock. In connection with this, the firm also plans to grant the underwriters an option to purchase around $11.0 million of additional shares. All of the shares are being sold by ACADIA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze